AtonRa Partners’s Neurocrine Biosciences NBIX Stock Holding History

AtonRa Partners’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$659K	Sell	5,002 -560	-10%	-$64.5K	1.31%	17
2023 Q3	$626K	Sell	5,562 -1,293	-19%	-$136K	1.31%	14
2023 Q2	$646K	Sell	6,855 -456	-6%	-$44.6K	1%	28
2023 Q1	$740K	Sell	7,311 -688	-9%	-$71.6K	1.08%	28
2022 Q4	$955K	Sell	7,999 -3,187	-28%	-$373K	1.22%	27
2022 Q3	$1.19M	Sell	11,186 -255	-2%	-$25.9K	1.17%	26
2022 Q2	$1.11M	Sell	11,441 -2,148	-16%	-$198K	1.03%	35
2022 Q1	$1.27M	Buy	13,589 +680	+5%	+$57.6K	0.69%	66
2021 Q4	$1.1M	Buy	12,909 +1,091	+9%	+$100K	0.38%	87
2021 Q3	$1.13M	Buy	11,818 +915	+8%	+$86.4K	0.38%	93
2021 Q2	$1.06M	Sell	10,903 -17,510	-62%	-$1.68M	0.39%	90
2021 Q1	$2.76M	Buy	28,413 +2,986	+12%	+$313K	1.23%	30
2020 Q4	$2.44M	Buy	+25,427	New	+$2.46M	1.2%	35

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AtonRa Partners's NBIX Position: Q4 2023 in Review

AtonRa Partners reduced its Neurocrine Biosciences (NBIX) stake by 10% in Q4 2023, selling an estimated $64.5K and leaving 5,002 shares worth $659K. The position accounts for 1.31% of the portfolio, ranked #17.

AtonRa Partners first reported a position in NBIX in Q4 2020 and has held it in 13 quarters since. The position peaked at $2.76M in Q1 2021. 554 funds tracked by Wall St. Rank hold NBIX as of Q4 2023.

AtonRa Partners held 5,002 shares of Neurocrine Biosciences worth $659K as of Q4 2023.
AtonRa Partners sold 560 Neurocrine Biosciences shares in Q4 2023, an estimated $64.5K.
Neurocrine Biosciences made up 1.31% of AtonRa Partners's portfolio in Q4 2023, its #17 holding.
AtonRa Partners first reported a position in Neurocrine Biosciences in Q4 2020 and has held it in 13 quarters since.
AtonRa Partners's Neurocrine Biosciences position peaked at $2.76M in Q1 2021.
554 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2023.

Based on AtonRa Partners's 13F filing for Q4 2023, filed 5 Feb 2024.